International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)

Retinal Organoids in Precision Ophthalmology: Advances, Applications, and Translational Challenges

Sameer Ahmad Mir Gojar[1], Achla Sharma[1]*, Mohita Thakur[1], Pallavi Chandel[1]

[1]School of Pharmacy, Deshbhagat University, off to NH-44, Amloh Road, Mandi Gobindgarh District Fatehgarh Sahib, Punjab- 14, Mandi Gobindgarh, Punjab 147301, India..

ABSTRACT

Retinal organoids have emerged as powerful three-dimensional models that recapitulate human retinal development, cellular diversity, and disease-relevant phenotypes with unprecedented fidelity. Derived from pluripotent stem cells, these organoids provide patient-specific systems for studying inherited and degenerative retinal disorders, enabling mechanistic insights that are often inaccessible in animal models. Advances in bioengineering including microfluidics, bioreactors, RPE co-culture, and 3D bioprinting have significantly improved organoid maturation, photoreceptor functionality, and structural organization. These high-fidelity systems now play a central role in precision ophthalmology, supporting gene therapy validation, CRISPR-based genome editing, drug screening, toxicity profiling, and preclinical transplantation studies. Early clinical interfaces have also begun to emerge, particularly through organoid-derived RPE implantation and the use of patient-specific organoids to guide personalized therapeutic decisions. Despite these advancements, challenges remain, including biological immaturity, lack of vasculature, variability between batches, long culture timelines, and ethical considerations surrounding donor privacy and regulatory oversight. Continued efforts toward standardization, integration of aging features, development of organoid biobanks, and adoption of AI-driven analysis will accelerate the safe and effective translation of retinal organoid technologies into clinical therapies. Collectively, retinal organoids represent a transformative platform poised to reshape the future of personalized vision care.

Keywords: ***Retinal organoids, Precision ophthalmology, Gene therapy, Disease modelling, Regenerative medicine, Stem cell technology***

***Corresponding Author:**
Miss. Achla Sharma
School of Pharmacy, Desh Bhagat University, off to NH-44, Amloh Road, Mandi Gobindgarh District Fatehgarh Sahib, Punjab- 14, Mandi Gobindgarh, Punjab 147301, India
Email; achlasharma1997@gmail.com
ORCID ID: 0009-0006-5180-2689.

1. Introduction

The retinal diseases as a whole are among the significant causes of visual impairment and blindness in the world, with hundreds of millions of people of all ages being affected. Other causes like age related macular degeneration (AMD), diabetic retinopathy (DR), inherited retinal disorders (IRDs) and retinal detachment are all causes of this global burden with AMD alone estimated to affect almost 200 million individuals by the year 2040 [1]. The retinal pathologies should only increase due to the aging of the population and an increase in the occurrence of metabolic diseases such as diabetes. The depth of the vision loss is not only personal

disability, but also mental well-being, independence, socioeconomic stability, and the healthcare systems. In such a way, the necessity of better strategies of diagnosis, treatment and prevention of retinal diseases has become one of the urgent concerns at the international level [2].

In spite of the current developments related to imaging technologies and treatment, there exist major shortcomings in the treatment of retinal diseases. The existing diagnostics are based on structural imaging (e.g., OCT, fundus photography) that frequently detects disease once severe damage has been done to prevent the implementation of early intervention [3]. Although therapeutic options would be effective in some disorders, they are frequently only palliative but not restorative. In particular, anti-VEGF therapy, which includes, among others, neovascular AMD and diabetic macular edema, has revolutionized their treatment modalities, but necessitates regular intravitreal injections, carries the risk of complications, and not all patients respond to it [3]. In several IRDs (such as retinitis pigmentosa and Stargardt disease) there has been no effective treatment, and the genetic heterogeneity of the underlying pathophysiology can be a significant challenge. Additionally, the small regenerative ability of the eye prevents the viability of traditional methods that seek to repair the harmed photoreceptors or retinal pigment epithelium (RPE). These constraints demonstrate the pressing importance of new solutions that would consider disease mechanisms on both a cellular and molecular scale [4].

Retinal diseases, especially hereditary degenerative ones, are usually caused by the different types of genetic background and multiple pathologic pathways. A therapeutic approach that fits everyone is thus inadequate [5]. The concept of precision medicine customization of interventions regarding the genetic and biological profile of an individual has become a promising trend in the field of ophthalmology. Examples of this change are gene therapies, CRISPR-based genome editing, cell replacement strategies and advanced biologics [6]. Nevertheless, they need proper human-specific models in order to determine efficacy and safety. Also, regenerative strategies that can reformation of intricate retinal structure and substitute of destroyed cells are needed in situations where irreversible loss of photoreceptors has already taken place. Individualized and regenerative approaches provide the possibility not only to stop the disease development but also to recover the sight, which has recently become an unrealistic goal in the majority of retinal disorders [7].

Three-dimensional, self-organizing retinal tissues Three-dimensional self-organizing retrial tissues, which represent human pluripotent stem cell retinas, have quickly become a game-changer in ophthalmic research in meeting numerous unmet needs. Such organoids recap the human retina, cellular diversity, and architecture in vitro, enabling unprecedented access to the developmental processes and disease mechanisms during early development [8]. Retinal organoids engineered by the induction of the pluripotent stem cell (iPSC) of patients allow the modeling of genetic diseases in the environment of an individual genome, which makes them very important both in the field of mechanistic research and in the evaluation of personalized therapies [9]. Besides, they can be used to assess gene therapy vectors, screen drugs, and create transplantable retinal cells that could restore visual functions. Further developments in bioengineering including microfluidics, bioreactors and co-culture with RPE are further improving the maturity of organoids, photoreceptor activity and scalability, making retinal organoids the most suitable tissue in precision ophthalmology [10].

The current status of retinal organoid technology and its growing significance in precision medicine are summarized in this review. We go over the biological underpinnings of organoid development, showcase engineering advancements that improve their physiological relevance, and investigate their uses in drug and gene therapy testing, disease modelling, and regenerative techniques [11]. Preclinical and early clinical developments that indicate the translational potential of organoid-based treatments are also described in the review. Lastly, we evaluate the current obstacles, such as technical, moral, and legal issues, and suggest future paths for incorporating retinal organoids into clinical ophthalmology. When taken as a whole, these subjects offer a thorough assessment of retinal organoids as a potent tool for improving retinal disease diagnosis, treatment, and individualized care [12].

2. Development and Biology of Retinal Organoids

Retinal organoids, which offer an in vitro system that closely resembles the sequence of human retinal formation, constitute a significant advancement in regenerative and developmental ophthalmology [13]. These organoids allow for in-depth research on early morphogenesis, cellular differentiation, and disease-specific changes that are not possible in living humans by reproducing the temporal and spatial events of embryonic retina development [14].

2.1 Origins from Pluripotent Stem Cells

Human pluripotent stem cells (hPSCs), such as induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), are used to create retinal organoids [15]. ESCs are derived from early-stage embryos and have a strong capacity for differentiation and inherent pluripotency. Reprogrammed from adult somatic cells using specific transcription factors, induced pluripotent stem cells (iPSCs) provide comparable developmental potential and allow for patient-specific disease modelling [16]. When given the right biochemical cues and microenvironmental conditions, both ESCs and iPSCs can self-organize into three-dimensional retinal tissues [17]. Retinal organoid technology is based on their capacity to differentiate into all major retinal lineages, including photoreceptors, bipolar cells, ganglion cells, Müller glia, amacrine, and horizontal cells. Crucially, organoids can reflect specific pathogenic mutations due to the genetic identity preserved in iPSCs, which makes them essential instruments for precision medicine [18].

2.2 Key Stages of Differentiation

The major stages of vertebrate retinogenesis are recapitulated in retinal organoid differentiation, which advances through highly conserved developmental events. PAX6, RAX, LHX2, and SIX3 are among the eye field transcription factors (EFTFs) that are expressed after pluripotent stem cells undergo neural induction in the first stage [19]. These molecules start the development of domains that resemble eye fields and push cells in the direction of becoming retinal progenitors. This stage is similar to the early stages of embryonic development, when retinal primordia develop from the anterior neural plate [20].

Self-organizing cell aggregates produce optic vesicle-like evaginations after the eye field is established. These evaginations then invaginate to form optic cup-like structures [21]. A neuroretinal domain and, on occasion, areas resembling retinal pigment epithelium (RPE) are present in these optic cups. This morphogenetic change illustrates the inherent ability of stem cells to simulate intricate embryonic folding and is a defining feature of organoid maturation [22].

The neuroretinal tissue develops into unique laminar structures that resemble the native retina over time. Bipolar cells, Müller glia, amacrine and horizontal cells, and retinal ganglion cells (RGCs) emerge first. The outermost layer is populated by photoreceptor precursors, which replicate the spatial arrangement of the developing retina [23]. Current protocols produce highly ordered layers with suitable molecular signatures, though complete adult-like lamination is not always attained. Cones and rods of photoreceptor cells start expressing important proteins like CRX, RECOVERIN, opsins, and elements of the photo transduction cascade by 120–180 days in culture [24]. Structures resembling outer segments may form, especially in engineered systems or under ideal culture conditions (e.g., microfluidics, RPE co-culture). Recent advancements have greatly improved the structural and functional characteristics of photoreceptors in organoids, despite the fact that they usually exhibit partial maturity [25].

2.3 Current Protocol Innovations

The improvement of retinal organoids' reproducibility, maturation, and scalability has been the focus of recent developments. The suspension culture used in traditional protocols enables aggregates to self-organize without attachment [26]. On the other hand, hybrid systems that combine early adherent induction with later suspension phases have improved optic cup formation efficiency and decreased batch variability. Additionally, improved nutrient exchange and more consistent organoid growth are supported by hybrid protocols [27].

The accuracy of retinal organoid differentiation and overall organoid quality have been greatly improved by targeted manipulation of important developmental pathways. Inhibiting BMP and TGF-β signaling strengthens early neural induction and steers pluripotent stem cells toward a neuroectodermal destiny [28]. By encouraging appropriate optic vesicle patterning and establishing early retinal identity, Wnt pathway modulation further refines this process. FGF and retinoic acid signaling are crucial for directing photoreceptor specification and encouraging their structural and functional maturation as development advances. Culture supplements like taurine, insulin, and N2/B27 additives promote the development of outer segment-like structures, improve photoreceptor survival, and support metabolic stability [29]. These improvements reduce variability among organoids and enhance the fidelity of retinal cell differentiation, which are significant developments for producing repeatable and clinically relevant retinal tissue.

Figure 1 illustrates the sequential developmental stages involved in retinal organoid formation. The process begins with pluripotent stem cells that differentiate into the eye field, followed by the formation of the optic vesicle [30]. This structure further invaginates to generate the optic cup, which subsequently organizes into distinct retinal layers. Ultimately, these layers mature into functional photoreceptors, reflecting key stages of in vivo retinal development [31].



Figure 1. Developmental Stages of Retinal Organoid Formation

This figure depicts the stepwise progression of retinal organoid development from pluripotent stem cells. Stem cells first specify into an eye field domain, which then gives rise to the optic vesicle. Subsequent morphogenesis forms the optic cup, establishing early retinal architecture. The optic cup differentiates into organized retinal layers, eventually leading to the maturation of photoreceptors. This timeline reflects the major transitions that parallel in vivo human retinal development.

3. Technological Advancements Enhancing Organoid Fidelity

Although many aspects of human retinogenesis are successfully replicated by retinal organoids, maturation, nutrient delivery, and structural organization are restricted by conventional culture systems [32]. The physiological relevance of retinal organoids has significantly increased due to recent engineering and biotechnological advancements that support cell specialization, improve nutrient diffusion, improve oxygenation, and enable more controlled microenvironments. With the help of these technologies, the field is getting closer to creating organoids that are structurally, functionally, and long-term stable like the human retina [33].

3.1 Microfluidics and Retina-on-a-Chip Systems

One of the most significant developments for enhancing retinal organoid physiology is microfluidic technology. These systems incorporate organoids into Retina-on-a-Chip (RoC) platforms, which are tiny devices that provide precise control over mechanical cues, fluid flow, and nutrient availability [34]. For retinal organoid culture, this system has a number of important benefits. Continuous perfusion lowers the risk of central necrosis by effectively eliminating waste and supplying a steady supply of nutrients [35]. Diffusion constraints that normally prevent photoreceptor maturation in static cultures are overcome by increased oxygenation. Precise evaluation of cell-cell interactions is made possible by its compartmentalized design, which facilitates co-culture with retinal pigment epithelium (RPE). The platform also enables real-time monitoring, including calcium-dynamics measurements, electrophysiological recording, and live imaging, providing a thorough understanding of organoid development and function [36]. RoC systems have demonstrated improved expression of visual cycle proteins, increased synaptic activity, and improved development of photoreceptor outer segments. Additionally, they provide robust drug testing platforms that enable physiologically relevant pharmacokinetics and controlled dosing. Microfluidic systems represent a significant advancement in precision drug screening and toxicity prediction due to their capacity to incorporate patient-specific organoids [37].

3.2 Bioreactor Culture Improvements

Through dynamic fluid movement, bioreactors offer controlled, scalable environments that maximize nutrient delivery and oxygenation. In contrast to static cultures, bioreactors produce mild agitation that improves organoid survival by lowering metabolite concentration gradients [38]. Because they increase overall survival and decrease apoptosis, especially in the inner retinal layers, bioreactor systems provide substantial benefits for retinal organoid culture. Through consistent nutrient distribution, they support superior lamination and stratification and enhance photoreceptor differentiation, producing more rod and cone precursors [39]. Large-batch production appropriate for drug screening and transplantation research is made possible by their scalable design. When compared to conventional suspension cultures, bioreactors show notable improvements in outer segment elongation, mitochondrial integrity, and rhodopsin expression [40].

4.3 Co-culture with RPE and Vascular Mimetic Systems

For metabolic support, phagocytosis, and visual pigment recycling, retinal photoreceptors in vivo mainly depend on the choroidal vasculature and the underlying retinal pigment epithelium (RPE). Conventional organoids' functional maturity is limited because they frequently lack a strong, polarized RPE interface and do not include vasculature [41]. By encouraging the development of more distinct photoreceptor outer segments, enhancing visual cycle activity through effective retinoid recycling, and boosting photoreceptor survival through metabolic support and phagocytosis, RPE co-culture systems dramatically improve retinal organoid maturation. Additionally, co-culture improves the polarity and organization of the outer layers of the retina, and the incorporation of RPE sheets or RPE-like cells results in structures that are more similar to the outer retina of humans [42]. Vascular-mimetic techniques include bioprinted vascular scaffolds embedded with organoids, endothelial co-culture to simulate blood–retina barrier formation, and microfluidic nutrient-delivery channels to address the lack of native vasculature. These systems enhance the distribution of nutrients, promote long-term viability, and increase the ability of retinal organoids to simulate vascular occlusion disorders, diabetic retinopathy, and ischemia [43].

3.4 3D Bioprinting and Scaffold-Based Engineering

Strong methods to direct retinal organization, encourage cellular alignment, and improve functional maturation are provided by 3D bioprinting and biomaterial scaffolds. By precisely positioning retinal progenitor cells, RPE cells, extracellular matrix elements, and supportive stromal cells, bioprinting makes it possible to create layered, retina-like structures with enhanced orientation and synaptic connectivity [44]. In addition, biomaterial scaffolds like fibrin, gelatin, PLGA, and electrospun nanofibers offer platforms that enhance survival and integration during photoreceptor transplantation, directional cues for axon guidance and photoreceptor alignment, mechanical support for laminar structure formation, and improved nutrient diffusion to minimize central necrosis [45]. Notably, axonal projections from retinal ganglion cells have been guided toward target tissues using electrospun scaffolds, simulating retinogeniculate pathways. Retinal constructs with mature photoreceptors, functional synapses, defined RPE interactions, and controlled vascular mimicry are now possible thanks to emerging combined approaches that integrate bioprinting, microfluidics, and scaffold engineering. This represents a significant advancement toward high-fidelity retinal organoid systems [46].

Figure 2 depicted the engineering techniques used to improve retinal organoid development and physiological relevance. The evolution from basic 2D cultures to intricate 3D systems, co-cultures, and structured tissue-level models is depicted in Panel (a), emphasizing the rise in model complexity toward organoids that are relevant to humans. Panel (b) illustrates bioprinting techniques, which produce structured, multicellular structures by carefully depositing various cell types within biomaterials. Microfluidic and perfusion systems that enhance nutrient delivery, facilitate RPE–retina interactions, and encourage advanced retinal organization including the development of outer limiting membrane and photoreceptor segments are shown in panel (c). When combined, these technologies allow retinal organoid systems to become more developed, functional, and physiologically accurate [47].



Figure 2. Engineering Technologies Enhancing Retinal Organoid Maturation

(a) *Increasing model complexity from basic 2D cultures to advanced 3D co-cultures and tissue-level systems, progressing toward human-relevant organoid models.* ***(b)*** *Bioprinting strategies that enable precise deposition of multiple cell types within biomaterials to generate organized, multicellular retinal constructs.* ***(c)*** *Microfluidic and perfusion platforms that enhance nutrient delivery, support RPE–retina interactions, and promote formation of structurally mature features such as the outer limiting membrane and photoreceptor segments.*

5. Applications of Retinal Organoids in Precision Ophthalmology

5.1 Patient-Specific Disease Modeling

Inherited retinal diseases (IRDs) can now be effectively modelled in a human-relevant setting using retinal organoids made from patient-specific induced pluripotent stem cells (iPSCs). They replicate disease phenotypes that are frequently impossible to capture in animal models because they preserve the donor's precise genetic background [48]. Organoids display distinctive features such as photoreceptor degeneration, opsin mislocalization, lipid accumulation, and increased susceptibility to oxidative stress for diseases like retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease, and age-related macular degeneration (AMD). Crucially, these models show how particular mutations affect retinal development and function over time, offering insights into genotype phenotype correlations [49]. This makes retinal organoids a key component of personalized ocular medicine by enabling the identification of early disease mechanisms, validation of pathogenic variants, and patient stratification for targeted therapeutic interventions [50].

5.2 Gene Therapy Development and Validation

Because they provide a biologically accurate human retinal system for testing vector performance, gene delivery efficiency, and therapeutic rescue, retinal organoids are essential to the development and assessment of gene therapies [51]. For a number of IRDs, such as RPGR-associated X-linked retinitis pigmentosa, CRX-related LCA, RP2 deficiency, and ABCA4-associated Stargardt disease, adeno-associated virus (AAV) vectors have been tested in organoids [52]. These investigations show improved photoreceptor survival, normalization of molecular pathways, and restoration of proper protein localization. Furthermore, organoids offer a perfect platform for genome editing techniques like CRISPR/Cas9, which allow for the effective correction of harmful mutations, allele-specific editing, and evaluation of off-target effects [53]. New methods such as REVeRT splicing strategies, which are intended for large genes that are too big for AAV packaging, have also been validated in organoids, demonstrating functional recovery and successful reconstitution of full-length transcripts. All things considered, organoids advance gene therapies toward clinical translation by bridging the gap between in vitro testing and in vivo validation [54].

5.3 Drug Screening and Toxicity Studies

Because of their human-specific cellular makeup and capacity to simulate disease-relevant pathways, retinal organoids are being used more and more for drug discovery, high-throughput screening, and toxicity assessment [55]. For the purpose of screening small molecules, repurposed FDA-approved medications, and substances that target photoreceptor metabolism, oxidative stress, or neuroprotection, large batches of organoids can be created. Compared to 2D cultures or animal models, their intricate 3D architecture enables more precise therapeutic response prediction [56]. Personalized drug testing is made possible by patient-derived organoids, which can identify responders versus nonresponders prior to clinical trials and reveal mutation-specific sensitivities [57]. Additionally, they offer early indicators of drug-induced toxicity, such as decreased synaptic activity, RPE dysfunction, and photoreceptor apoptosis. Because of these features, retinal organoids are positioned as cutting-edge platforms for assessing therapeutic suitability, safety, and efficacy in precision medicine [58].

5.4 Cell Replacement and Vision Restoration

Retinal organoids are renewable sources of organized retinal tissue, photoreceptors, and retinal pigment epithelium (RPE) cells that can be transplanted into retinas that are degenerating. Preclinical research has shown that photoreceptor sheet grafts and precursors derived from organoids can survive in the host retina, integrate with the remaining retinal circuits, and form synaptic connections with horizontal and bipolar cells [59]. Long-term survival, structural stability, and cell alignment are further improved by co-transplantation with RPE or scaffold-supported implantation. Significantly, it has been demonstrated that transplanted organoid-derived cells improve optokinetic responses, pupillary reflexes, and electroretinogram (ERG) signals in animal models, thereby restoring functional vision [60]. These results demonstrate the potential of retinal organoids as a basis for regenerative techniques intended to restore vision in advanced retinal degeneration, a field with great potential for clinical use in the future [61].

The main uses of retinal organoids in research, treatment development, and disease modelling are compiled in Table 1. It demonstrates how organoids are used to study the development of the human retina, look into genetic and degenerative diseases, assess the toxicity and effectiveness of drugs, and investigate methods for replacing photoreceptors or RPE cells [62].

Table 1: Applications of Retinal Organoids and Representative Studies

Sr. No.	Application	Key Finding	Reference
1	RP Disease Modeling (RPGR)	RPGR-mutant organoids show rhodopsin mislocalization; corrected with AAV-RPGR.	[63]
2	RP Disease Modeling (RHO)	RHO-mutant organoids exhibit dominant-negative photoreceptor degeneration.	[64]
3	LCA Modeling (CRX)	CRX-mutant organoids show absent opsin expression; restored by AAV-CRX.	[65]
4	LCA Modeling (CEP290)	CRISPR editing corrects CEP290 mutation and restores ciliogenesis.	[66]
5	LCA Modeling (AIPL1)	AIPL1-mutant organoids accumulate cGMP; drug rescue reduces toxicity.	[67]
6	Stargardt Disease (ABCA4)	ABCA4-mutant organoids accumulate bisretinoids; dual AAV restores function.	[68]
7	AMD Genetic Modeling	Organoids with AMD alleles show heightened oxidative stress.	[69]
8	DR Modeling	High-glucose organoid exposure triggers vascular-like stress markers.	[70]
9	Retinal Detachment Modeling	Mechanical stress in organoids induces photoreceptor apoptosis patterns.	[71]
10	RP2 Gene Therapy	AAV2/5-RP2 restores photoreceptor survival and ONL thickness.	[72]
11	RPGR Gene Therapy	AAV2(7m8)-RPGR normalizes rhodopsin distribution.	[73]
12	CRISPR Base Editing	Base editors correct point mutation in RP organoids.	[74]
13	Prime Editing in IRDs	Prime editing improves editing precision in patient organoids.	[75]
14	REVeRT Splicing (USH2A)	RNA trans-splicing restores large gene transcripts in organoids.	[76]
15	Drug Screening – Neuroprotection	Fenofibrate protects cones in MacTel2 organoids.	[77]

16	Drug Screening – Anti-inflammatory	Complement inhibitors reduce AMD-related stress in organoids.	[78]
17	Drug Screening – Anti-apoptotic	BDNF analogs improve photoreceptor survival under stress.	[79]
18	Toxicity – Small Molecules	Sunitinib identified as cone-toxic compound in organoids.	[80]
19	Toxicity – Chemotherapy Agents	Cisplatin causes dose-dependent photoreceptor death in organoids.	[81]
20	Toxicity – Environmental Agents	Organoids detect phototoxicity from retinal light exposure.	[82]
21	Photoreceptor Transplantation	Transplanted photoreceptors integrate and form synapses in rodents.	[83]
22	RPE Transplantation	Organoid-derived RPE supports host photoreceptor survival.	[84]
23	Full-Thickness Retinal Sheet Transplant	Retinal sheet grafts improve ERG responses in degeneration models.	[85]
24	Optic Cup Tissue Engineering	Engineered optic cups show improved lamination and ganglion cell survival.	[86]
25	Vision Restoration	Transplanted organoid-derived cells restore light-driven behavior.	[87]

6. Preclinical Insights and Early Clinical Translation

6.1 Preclinical Transplantation Studies

Retinal organoids have the potential to restore visual function in degenerative retinal conditions, according to preclinical transplantation studies using rodent and large-animal models. Transplanting organoid-derived photoreceptor precursors or retinal sheet grafts has produced strong survival, enhanced lamination, and the development of synaptic connections with host bipolar and horizontal cells in rodent models of advanced photoreceptor loss [88]. These grafts show expression of synaptic markers, indicating functional integration, in addition to structural alignment with the host outer nuclear layer. By demonstrating improved maturation of cone-rich regions and increased survival of transplanted photoreceptors, porcine models, which closely mimic human retinal anatomy, have further validated these findings. When taken as a whole, these studies offer compelling proof that organoid-derived cells can engraft, integrate, and aid in signal transmission a significant advancement toward potential clinical use [88].

6.2 Gene Therapy Testing Pipelines

In preclinical pipelines for testing gene therapies, retinal organoids have emerged as key platforms, especially for inherited retinal diseases where human-specific models are crucial. In both patient-derived and gene-edited organoids, AAV vectors containing therapeutic genes like RPGR, CRX, RP2, and ABCA4 have undergone extensive testing [89]. These studies consistently show improved photoreceptor morphology, reversal of early degenerative phenotypes, and restoration of proper protein localization. For instance, AAV-CRX restores opsin expression and photoreceptor maturation in CRX-linked Leber congenital amaurosis, whereas AAV2 (7m8)-RPGR corrects rhodopsin mislocalization in X-linked retinitis pigmentosa models [90]. In modeling Stargardt

disease, dual-vector methods like REVeRT-mediated ABCA4 reconstitution have also demonstrated encouraging efficacy. The predictive value of organoids in evaluating gene therapy performance before in vivo testing is demonstrated by functional outcomes such as improved outer segment formation, normalization of transcriptomic profiles, and improved cell survival [91].

6.3 Early Human Clinical Interfaces

Early clinical uses of tissues and instruments derived from retinal organoids are starting to connect lab research with actual patient care. With acceptable safety profiles and early indications of functional stabilization, organoid-derived retinal pigment epithelium (RPE) has already advanced into human trials for conditions like geographic atrophy and Stargardt disease [92]. Beyond transplantation, patient-derived organoids are increasingly being used to inform personalized treatment choices by validating pathogenic variants found through genetic testing and forecasting treatment response [93]. Organoids have occasionally been used to assess whether experimental gene therapies are appropriate for particular mutations or to find possible side effects prior to clinical use. This incorporation of organoids into clinical pipelines highlights their expanding use in ophthalmology as precision instruments to support imaging, genetics, and customized treatment planning [94].

Table 2 lists new clinical interfaces where organoid-derived tissues, like RPE sheets, are being used in early human trials for diseases like Stargardt disease and dry AMD. A significant advancement in precision ophthalmology is the growing use of organoids to direct individualized clinical decisions, such as variant validation and therapy suitability. The entries in Table 2 collectively demonstrate the depth and scope of retinal organoid applications, highlighting their significance as a link between research in the lab and potential clinical treatments [95].

Table 2*:* Preclinical and Early Clinical Use of Retinal Organoids

Sr. No.	Category	Study Type / Application	Key Finding	Reference
1	Preclinical Transplantation	Photoreceptor transplantation in rodent models	Organoid-derived rods and cones survive and integrate into host retina.	[96]
2	Preclinical Transplantation	Retinal sheet grafts in RCS rats	Improved ERG responses and visual behavior.	[97]
3	Preclinical Transplantation	Transplantation into porcine retina	Enhanced photoreceptor survival and lamination.	[98]
4	Preclinical Integration	Synaptic formation post-transplant	Transplanted cells form functional synaptic connections.	[99]
5	Preclinical Retinal Circuitry	Axonal extension from organoid RGCs	RGCs extend axons along engineered scaffolds.	[100]
6	Preclinical – Gene Therapy	AAV-RPGR testing in RP organoids	Corrects rhodopsin mislocalization.	[101]
7	Preclinical – Gene Therapy	AAV-CRX delivery	Restores opsin expression in CRX-LCA organoids.	[102]
8	Preclinical – Gene Therapy	AAV-RP2 therapy testing	Improves photoreceptor survival and morphology.	[103]
9	Preclinical – Gene Therapy	AAV-ABCA4 (dual vector)	Reconstitutes ABCA4 expression in Stargardt organoids.	[104]
10	Preclinical – CRISPR Editing	Correction of CEP290 mutation	Restores ciliogenesis in LCA organoids.	[105]

11	Preclinical – Prime Editing	Prime editing in RP organoids	Efficient correction of point mutations with minimal off-targets.	[106]
12	Preclinical – Drug Screening	High-throughput neuroprotective screening	Fenofibrate reduces photoreceptor loss.	[107]
13	Preclinical – Drug Screening	Screening for anti-oxidative agents	Identifies compounds that reduce AMD-like stress.	[108]
14	Preclinical – Toxicity	Small molecule toxicity profiling	Detects cone-specific toxicity of sunitinib.	[109]
15	Preclinical – Toxicity	Chemotherapy toxicity modeling	Cisplatin induces dose-dependent photoreceptor apoptosis.	[110]

7. Limitations and Challenges in Translational Use

Retinal organoids still have a number of biological constraints that limit their translational potential, despite significant progress. The absence of a vascular network, which limits the diffusion of nutrients and oxygen and causes central necrosis in larger or longer-term cultures, is a basic problem [111]. This restriction has a direct impact on the development of photoreceptors, which frequently lack the fully formed outer segments necessary for strong phototransduction and remain structurally underdeveloped. Furthermore, organoids are unable to accurately replicate the intricacy of human retinal circuitry; functional ON/OFF pathways do not develop to physiological levels, and synaptic organization is still lacking [112]. The majority of organoids only develop sporadic RPE patches rather than a continuous, polarized monolayer due to inconsistent interaction with the retinal pigment epithelium (RPE), which limits their capacity to simulate diseases involving the RPE–photoreceptor axis. These biological limitations show that in order to improve fidelity to the native retina, better engineering and co-culture techniques are required [113].

Even mature organoids show relatively weak light responses compared to in vivo retina, reflecting incomplete physiological maturation; batch-to-batch variability, where organoids generated from the same protocol or cell line frequently exhibit differences in size, morphology, and cell composition, complicates reproducibility across laboratories and limits scalability for drug screening or therapeutic manufacturing; long culture durations, often exceeding 150 to 200 days for mature photoreceptor development. Standardized procedures, automated systems, and strict quality control frameworks will be necessary to overcome these technical constraints [114].

As the field develops, a number of ethical and legal issues raised by the production and clinical application of retinal organoids must be resolved. Concerns regarding informed consent, privacy, and the possibility of genetic re-identification are raised by donor-derived iPSCs, particularly since organoids preserve distinct patient-specific genomic data. Ethical concerns regarding the degree of humanization in animal models are also raised by the use of organoids in human animal chimeric research, especially for neural integration or transplantation [115]. Ownership, benefit-sharing, and fair access to organoid-derived treatments are just a few of the complications brought about by the commercialization of patient-derived organoids. Regulations governing organoid research and clinical translation are currently disjointed and lack uniform standards for production, quality assurance, and safety evaluation. To ensure responsible, ethical, and safe advancement toward clinical application, specific regulatory pathways for organoids must be established [116].

8. Future Directions

The creation of reliable standardization and quality control pipelines is critical to the future of retinal organoid research. Inconsistencies in organoid quality, cellular composition, and maturation are caused by current differentiation protocols, which frequently differ significantly between labs [117]. For cross-study comparisons and clinical translation, standardized protocols for stem cell sourcing, differentiation stages, culture conditions, and endpoint analyses must be established. Reproducibility and batch variability will be reduced with the use of automated bioreactors, AI-assisted morphology evaluation, and molecular QC checkpoints like transcriptomic and epigenetic profiling. To advance organoid-derived products into regulated clinical settings, "release criteria" akin to those used for cell therapy manufacturing must be developed. The incapacity of existing retinal organoids to accurately replicate aging processes, which are essential to late-onset retinal disorders like diabetic retinopathy, glaucoma, and age-related macular degeneration, is a

significant drawback. Future models must include characteristics of cellular aging, such as inflammatory signalling, telomere shortening, mitochondrial dysfunction, and DNA damage accumulation [118]. To mimic "aged" retinal phenotypes, methods like progerin overexpression, oxidative stress induction, or metabolic manipulation are being investigated. It may also be possible to model long-term declines in extracellular matrix integrity and blood–retina barrier function by using sophisticated RPE co-culture or vascular mimicry. Aging-integrated organoids would be useful tools for researching the course of long-term diseases and for screening treatments that stop or reverse age-related retinal degeneration [119].

One of the most revolutionary paths for precision ophthalmology in the future is the creation of extensive biobanks of patient-derived retinal organoids. Organoids from genetically diverse people would be kept in these biobanks, allowing for the precise mapping of genotype–phenotype relationships and the identification of patient subgroups that react differently to treatments [120]. These biobanks could be used by clinical researchers and pharmaceutical companies to perform stratified preclinical testing, hastening the creation of tailored treatments. These living repositories would also eliminate the need for animal testing by enabling high-throughput screening campaigns to find therapeutic candidates specific to mutations. In the end, organoid biobanks could direct clinical trial enrollment criteria, enhance therapeutic outcome prediction accuracy, and facilitate individualized treatment choices [119].

AI integration with retinal organoid systems has the potential to transform therapeutic prediction, disease modeling, and analysis. High-dimensional imaging, electrophysiological data, and molecular profiles can be analyzed by machine learning algorithms to predict differentiation efficiency, model treatment responses, and detect subtle developmental abnormalities. Automated phenotyping and AI-assisted organoid tracking will greatly lessen human bias and speed up discovery. Additionally, computational models could guide experimental design and lessen laboratory workload by simulating disease progression or treatment effects across thousands of virtual organoid variants [121]. In order to produce individualized predictions for gene therapy or medication response, these AI organoid hybrid platforms may also incorporate patient-specific genomic data, ultimately assisting with precise clinical decision-making. The field needs to set up clinical-grade manufacturing pipelines that adhere to regulatory standards if retinal organoids are to realize their therapeutic potential. This includes xeno-free culture systems, standardized differentiation procedures, strict release requirements for organoid-derived grafts, and stem cell derivation that complies with Good Manufacturing Practices [122]. Automated culture systems, 3D bioprinting, and biomaterial scaffolds are examples of innovations that will aid in the production of reliable organoids fit for transplantation. To assess risks like immune responses, unchecked cell proliferation, or ectopic tissue formation, long-term safety studies will be necessary. Regulatory bodies will also need to create precise rules for organoid-based treatments, including specifications for sterility, potency tests, and product traceability. Retinal organoids may advance from research instruments to clinically approved regenerative treatments that can help patients with advanced retinal degeneration regain their vision as these pathways develop [123].

9. Conclusion

Retinal organoids have quickly developed into one of the most revolutionary instruments in contemporary ophthalmic research, providing previously unheard-of chances to study disease mechanisms, model human retinal development, and create individualized treatment plans. They are particularly well-suited for researching inherited retinal disorders and forecasting individual treatment responses, which is a crucial aspect of precision ophthalmology, due to their capacity to replicate patient-specific genetic backgrounds. Microfluidic platforms, bioreactor systems, RPE co-culture, vascular mimicry, and 3D bioprinting are examples of recent engineering advancements that have significantly improved organoid maturation and functional relevance, bringing these models closer to simulating the complexity of the human retina. In order to validate gene therapies, optimize genome editing tools, screen drugs, evaluate toxicity, and produce transplant-ready photoreceptors and RPE cells, retinal organoids are now essential platforms. The increasing translational impact of this technology is highlighted by early clinical applications, especially in RPE transplantation and personalized therapy design. However, there are still a number of issues that need to be resolved through standardized procedures, sophisticated QC systems, and organoid-specific regulatory frameworks. These issues include incomplete maturation, a lack of vasculature, batch variability, and ethical concerns. In the future, therapeutic discovery and clinical translation will be greatly accelerated by the integration of artificial intelligence, patient-derived organoid biobanks, and aging models. Retinal organoids have great potential to provide next-generation regenerative therapies and customized interventions that can improve patient care and restore vision with further development and thorough validation.

In Summary, retinal organoids have become potent models that closely resemble human retinal development and illness, allowing for accurate study of degenerative and inherited diseases. Microfluidics, bioreactors, and RPE co-culture are examples of engineering innovations that have greatly increased their maturity and translational relevance. These organoids are now essential platforms for preclinical transplantation research, drug screening, and gene therapy testing. Even though there are still issues like variability and insufficient vascularization, the field is moving closer to clinical application thanks to continuous innovation and standardization initiatives. In the end, retinal organoids have great potential to revolutionize future vision-restoring treatments and customized ophthalmic care.

Abbreviation Table

Abbreviation	Full Form
AMD	Age-Related Macular Degeneration
DR	Diabetic Retinopathy
IRDs	Inherited Retinal Disorders
OCT	Optical Coherence Tomography
RPE	Retinal Pigment Epithelium
hPSCs	Human Pluripotent Stem Cells
iPSCs	Induced Pluripotent Stem Cells
ESCs	Embryonic Stem Cells
EFTFs	Eye Field Transcription Factors
RGCs	Retinal Ganglion Cells
AAV	Adeno-Associated Virus
CRISPR	Clustered Regularly Interspaced Short Palindromic Repeats
RoC	Retina-on-a-Chip
ERG	Electroretinogram
ONL	Outer Nuclear Layer
PLGA	Poly(lactic-co-glycolic acid)
LCA	Leber Congenital Amaurosis
RP	Retinitis Pigmentosa
ABCA4	ATP-Binding Cassette Subfamily A Member 4
RHO	Rhodopsin
RP2 / RPGR	Retinitis Pigmentosa Protein 2 / Retinitis Pigmentosa GTPase Regulator
REVeRT	RNA Trans-Splicing Vector Technology
GMP	Good Manufacturing Practice

Acknowledgment

Author Contribution

S.A.M.G Data Analysis and interpretation, A.S Data collection and Conceptualization, M.T Visualization, P.C Writing the paper, A.S Study concept or design, Visualization.

Conflict of Interest

The authors declare no conflict of interest.

Source of Funding

There is no funding available to conduct this study.

References

1. Z. Zhang, Z. Xu, F. Yuan, K. Jin, and M. Xiang, "Retinal organoid technology: Where are we now?," 2021. doi: 10.3390/ijms221910244.
2. Z. B. Jin et al., "Stemming retinal regeneration with pluripotent stem cells," 2019. doi: 10.1016/j.preteyeres.2018.11.003.
3. S. J. Gasparini, S. Llonch, O. Borsch, and M. Ader, "Transplantation of photoreceptors into the degenerative retina: Current state and future perspectives," 2019. doi: 10.1016/j.preteyeres.2018.11.001.
4. M. Völkner, T. Kurth, and M. O. Karl, "The Mouse Retinal Organoid Trisection Recipe: Efficient Generation of 3D Retinal Tissue from Mouse Embryonic Stem Cells," in Methods in Molecular Biology, 2019. doi: 10.1007/978-1-4939-8669-9_9.
5. I. Martínez-Solís et al., "Neuroprotective Potential of Ginkgo biloba in Retinal Diseases," 2019. doi: 10.1055/a-0947-5712.
6. M. Daich Varela et al., "Artificial intelligence in retinal disease: clinical application, challenges, and future directions," 2023. doi: 10.1007/s00417-023-06052-x.
7. S. Zeng et al., "Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases," 2023. doi: 10.1016/j.addr.2023.114965.
8. Y. Tatour and T. Ben-Yosef, "Syndromic inherited retinal diseases: genetic, clinical and diagnostic aspects," 2020. doi: 10.3390/diagnostics10100779.
9. J. Sajovic, A. Meglič, D. Glavač, Š. Markelj, M. Hawlina, and A. Fakin, "The Role of Vitamin A in Retinal Diseases," 2022. doi: 10.3390/ijms23031014.
10. S. Zhu et al., "Screening of Common Retinal Diseases Using Six-Category Models Based on EfficientNet," Front. Med., 2022, doi: 10.3389/fmed.2022.808402.
11. B. L. Lam, B. P. Leroy, G. Black, T. Ong, D. Yoon, and K. Trzupek, "Genetic testing and diagnosis of inherited retinal diseases," 2021. doi: 10.1186/s13023-021-02145-0.
12. Manisha Dev and Pallavi Chandel, "Nanostructured Lipid Carriers in Pulmonary Drug Delivery: Progress and Prospects," Curr. Pharm. Res., pp. 131–143, 2025, doi: 10.63785/cpr.2025.1.1.131143.
13. M. Fathi, C. T. Ross, and Z. Hosseinzadeh, "Functional 3-Dimensional Retinal Organoids: Technological Progress and Existing Challenges," 2021. doi: 10.3389/fnins.2021.668857.
14. A. Jacobo Lopez et al., "Retinal organoids derived from rhesus macaque iPSCs undergo accelerated differentiation compared to human stem cells," Cell Prolif., 2022, doi: 10.1111/cpr.13198.
15. D. W. Rosales and Q. N. Mullen, Pluripotent stem cells. 2010. doi: 10.1201/9781003464594-27.
16. J. Collin et al., "Deconstructing Retinal Organoids: Single Cell RNA-Seq Reveals the Cellular Components of Human Pluripotent Stem Cell-Derived Retina," Stem Cells, 2019, doi: 10.1002/stem.2963.
17. O. Bar-Nur, H. A. Russ, S. Efrat, and N. Benvenisty, "Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells," Cell Stem Cell, 2011, doi: 10.1016/j.stem.2011.06.007.
18. T. Aoi et al., "Generation of pluripotent stem cells from adult mouse liver and stomach cells," Science (80-.)., 2008, doi: 10.1126/science.1154884.
19. J. Chen et al., "ZNF804A transcriptional networks in differentiating neurons derived from induced pluripotent stem cells of human origin," PLoS One, 2015, doi: 10.1371/journal.pone.0124597.
20. H. Lapillonne et al., "Red blood cell generation from human induced pluripotent stem cells: Perspectives for transfusion medicine," Haematologica, 2010, doi: 10.3324/haematol.2010.023556.
21. M. H. Chin et al., "Induced Pluripotent Stem Cells and Embryonic Stem Cells Are Distinguished by Gene Expression Signatures," Cell Stem Cell, 2009, doi: 10.1016/j.stem.2009.06.008.
22. Y. F. Chou et al., "The Growth Factor Environment Defines Distinct Pluripotent Ground States in Novel Blastocyst-Derived Stem Cells," Cell, 2008, doi: 10.1016/j.cell.2008.08.035.
23. H. Fukusumi et al., "Establishment of Human Neural Progenitor Cells from Human Induced Pluripotent Stem Cells with Diverse Tissue Origins," Stem Cells Int., 2016, doi: 10.1155/2016/7235757.

24. E. W. Kuijk, S. M. Chuva de Sousa Lopes, N. Geijsen, N. Macklon, and B. A. J. Roelen, "The different shades of mammalian pluripotent stem cells," 2011. doi: 10.1093/humupd/dmq035.
25. G. Kolios and Y. Moodley, "Introduction to stem cells and regenerative medicine," 2013. doi: 10.1159/000345615.
26. Y. A. Rim et al., "Different chondrogenic potential among human induced pluripotent stem cells from diverse origin primary cells," Stem Cells Int., 2018, doi: 10.1155/2018/9432616.
27. T. Begaj, R. Parikh, and D. Eliott, "Retina," in Pivotal Trials in Ophthalmology: A Guide for Trainees, 2021. doi: 10.1007/978-3-030-63978-5_5.
28. R. Akiba, M. Takahashi, T. Baba, and M. Mandai, "Progress of iPS cell-based transplantation therapy for retinal diseases," 2023. doi: 10.1007/s10384-022-00974-5.
29. H. Uyama, M. Mandai, and M. Takahashi, "Stem-cell-based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies," Dev. Growth Differ., 2021, doi: 10.1111/dgd.12704.
30. M. Li et al., "Development of human retinal organoid models for bisphenol toxicity assessment," Ecotoxicol. Environ. Saf., 2022, doi: 10.1016/j.ecoenv.2022.114094.
31. K. Ning et al., "Characterization of Primary Cilia Formation in Human ESC-Derived Retinal Organoids," Stem Cells Int., 2023, doi: 10.1155/2023/6494486.
32. Z. Shao, P. De Coppi, and F. Michielin, "Leveraging mechanobiology and biophysical cues in lung organoids for studying lung development and disease," 2023. doi: 10.3389/fceng.2023.1255783.
33. N. Tabibzadeh, L. M. Satlin, S. Jain, and R. Morizane, "Navigating the kidney organoid: insights into assessment and enhancement of nephron function," Am. J. Physiol. - Ren. Physiol., 2023, doi: 10.1152/ajprenal.00166.2023.
34. S. Ahearn-Ford, J. E. Berrington, and C. J. Stewart, "Development of the gut microbiome in early life," 2022. doi: 10.1113/EP089919.
35. M. J. Afzal, F. Javaid, M. Ilyas Yasin, S. Tayyaba, and M. Waseem Ashraf, "Fluidic Simulation and Optimization of Microchannels for Retinal Vein Occlusion (RVO) by Using Fuzzy Technique," Sci. Inq. Rev., 2023, doi: 10.32350/sir.73.04.
36. J. Cho, P. Sternberg, D. Colon-Ramos, and C. Teng, "Microfluidic platform to study pressureinduced changes in neurons," Investig. Ophthalmol. Vis. Sci., 2018.
37. S. Liu, Y. K. Chan, H. C. Shum, and J. Park, "Microfluidic model of the blood-retinal-barrier for permeability tests," in 23rd International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2019, 2019.
38. P. Fattahi et al., "Core–shell hydrogel microcapsules enable formation of human pluripotent stem cell spheroids and their cultivation in a stirred bioreactor," Sci. Rep., 2021, doi: 10.1038/s41598-021-85786-2.
39. K. Shahin and P. M. Doran, "Strategies for enhancing the accumulation and retention of extracellular matrix in tissue-engineered cartilage cultured in bioreactors," PLoS One, 2011, doi: 10.1371/journal.pone.0023119.
40. M. Bäumler et al., "Continuous Production of Ethanol, 1-Butanol and 1-Hexanol from CO with a Synthetic Co-Culture of Clostridia Applying a Cascade of Stirred-Tank Bioreactors," Microorganisms, 2023, doi: 10.3390/microorganisms11041003.
41. H. V. Danesh-Meyer et al., "Connexin43 mimetic peptide reduces vascular leak and retinal ganglion cell death following retinal ischaemia," Brain, 2012, doi: 10.1093/brain/awr338.
42. S. D. Ahmad, M. Cetin, R. E. Waugh, and J. L. McGrath, "A computer vision approach for analyzing label free leukocyte trafficking dynamics on a microvascular mimetic," Front. Immunol., 2023, doi: 10.3389/fimmu.2023.1140395.
43. L. Y. Chen, C. W. Cheng, J. J. Lin, and W. Y. Chen, "Exploring the effect of cholesterol in lipid bilayer membrane on the melittin penetration mechanism," Anal. Biochem., 2007, doi: 10.1016/j.ab.2007.04.039.
44. S. Zhang et al., "Convergence of 3D Bioprinting and Nanotechnology in Tissue Engineering Scaffolds," 2023. doi: 10.3390/biomimetics8010094.
45. J. Zhang, E. Wehrle, M. Rubert, and R. Müller, "3d bioprinting of human tissues: Biofabrication, bioinks and bioreactors," 2021. doi: 10.3390/ijms22083971.
46. Y. W. Ding, X. W. Zhang, C. H. Mi, X. Y. Qi, J. Zhou, and D. X. Wei, "Recent advances in hyaluronic acid-based hydrogels for 3D bioprinting in tissue engineering applications," 2023. doi: 10.1016/j.smaim.2022.07.003.

47. X. Y. Tang et al., "Human organoids in basic research and clinical applications," 2022. doi: 10.1038/s41392-022-01024-9.
48. S. M. Nam, T. A. Peterson, A. J. Butte, K. Y. Seo, and H. W. Han, "Explanatory model of dry eye disease using health and nutrition examinations: Machine learning and network-based factor analysis from a national survey," JMIR Med. Informatics, 2020, doi: 10.2196/16153.
49. H. V. Nguyen, Y. Li, and S. H. Tsang, "Patient-specific iPSC-derived RPE for modeling of retinal diseases," 2015. doi: 10.3390/jcm4040567.
50. A. L. Marsden and J. A. Feinstein, "Computational modeling and engineering in pediatric and congenital heart disease," 2015. doi: 10.1097/MOP.0000000000000269.
51. P. S. C. Leung, S. A. Shu, T. P. Kenny, P. Y. Wu, and M. H. Tao, "Development and validation of gene therapies in autoimmune diseases: Epidemiology to animal models," 2010. doi: 10.1016/j.autrev.2009.12.009.
52. F. Regent et al., "Nicotinamide Promotes Formation of Retinal Organoids From Human Pluripotent Stem Cells via Enhanced Neural Cell Fate Commitment," Front. Cell. Neurosci., 2022, doi: 10.3389/fncel.2022.878351.
53. A. Hays et al., "Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development," AAPS J., 2024, doi: 10.1208/s12248-023-00880-9.
54. L. Chang, P. Ruiz, T. Ito, and W. R. Sellers, "Targeting pan-essential genes in cancer: Challenges and opportunities," 2021. doi: 10.1016/j.ccell.2020.12.008.
55. D. D. Allen, R. Caviedes, A. M. Cárdenas, T. Shimahara, J. Segura-Aguilar, and P. A. Caviedes, "Cell lines as in vitro models for drug screening and toxicity studies," Drug Dev. Ind. Pharm., 2005, doi: 10.1080/03639040500216246.
56. C. Y. Huang et al., "Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons," Cell Rep., 2022, doi: 10.1016/j.celrep.2022.110643.
57. L. R. de Souza Neto et al., "In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery," 2020. doi: 10.3389/fchem.2020.00093.
58. P. Szymański, M. Markowicz, and E. Mikiciuk-Olasik, "Adaptation of high-throughput screening in drug discovery-toxicological screening tests," 2012. doi: 10.3390/ijms13010427.
59. R. Schick, N. Farah, A. Markus, A. Korngreen, and Y. Mandel, "Electrophysiologic characterization of developing human embryonic stem cell-derived photoreceptor precursors," Investig. Ophthalmol. Vis. Sci., 2020, doi: 10.1167/IOVS.61.11.44.
60. R. A. Pearson, C. Hippert, A. B. Graca, and A. C. Barber, "Photoreceptor replacement therapy: Challenges presented by the diseased recipient retinal environment," 2014. doi: 10.1017/S0952523814000200.
61. M. L. Scalabrino et al., "Intravitreal delivery of a novel AAV vector targets ON bipolar cells and restores visual function in a mouse model of complete congenital stationary night blindness," Hum. Mol. Genet., 2015, doi: 10.1093/hmg/ddv341.
62. T. A. V. Afanasyeva, J. C. Corral-Serrano, A. Garanto, R. Roepman, M. E. Cheetham, and R. W. J. Collin, "A look into retinal organoids: methods, analytical techniques, and applications," 2021. doi: 10.1007/s00018-021-03917-4.
63. W. L. Deng et al., "Gene Correction Reverses Ciliopathy and Photoreceptor Loss in iPSC-Derived Retinal Organoids from Retinitis Pigmentosa Patients," Stem Cell Reports, 2018, doi: 10.1016/j.stemcr.2018.02.003.
64. "Abstracts of the 17th International Symposium on Bioluminescence and Chemiluminescence - (ISBC 2012)," Luminescence, 2012, doi: 10.1002/bio.2341.
65. K. Kruczek et al., "Gene Therapy of Dominant CRX-Leber Congenital Amaurosis using Patient Stem Cell-Derived Retinal Organoids," Stem Cell Reports, 2021, doi: 10.1016/j.stemcr.2020.12.018.
66. K. Kruczek et al., "In vitro modeling and rescue of ciliopathy associated with IQCB1/NPHP5 mutations using patient-derived cells," Stem Cell Reports, 2022, doi: 10.1016/j.stemcr.2022.08.006.
67. M. Rashid et al., "Pathogenic variants of AIPL1, MERTK, GUCY2D, and FOXE3 in Pakistani families with clinically heterogeneous eye diseases," PLoS One, 2020, doi: 10.1371/journal.pone.0239748.
68. D. Sun et al., "Non-viral Gene Therapy for Stargardt Disease with ECO/pRHO-ABCA4 Self-Assembled Nanoparticles," Mol. Ther., 2020, doi: 10.1016/j.ymthe.2019.09.010.
69. T. J. Heesterbeek et al., "Complement activation levels are related to disease stage in AMD," Investig. Ophthalmol. Vis. Sci., 2020, doi: 10.1167/iovs.61.3.18.

70. D. Kirchem, M. Lynch, V. Bertsch, and E. Casey, “Modelling demand response with process models and energy systems models: Potential applications for wastewater treatment within the energy-water nexus,” 2020. doi: 10.1016/j.apenergy.2019.114321.
71. R. Avtar and S. Srivastava, “Mathematical Modeling of Exudative Retinal Detachment,” Appl. Math., 2017, doi: 10.4236/am.2017.81005.
72. S. Mookherjee et al., “Long-term rescue of cone photoreceptor degeneration in retinitis pigmentosa 2 (RP2)-knockout mice by gene replacement therapy,” Hum. Mol. Genet., 2015, doi: 10.1093/hmg/ddv354.
73. J. C. Kapetanovic, M. E. McClements, C. M. F. D. La Camara, and R. E. Maclaren, “Molecular strategies for RPGR gene therapy,” 2019. doi: 10.3390/genes10090674.
74. G. Borges, Y. Benslimane, and L. Harrington, “A CRISPR base editing approach for the functional assessment of telomere biology disorder-related genes in human health and aging,” Biogerontology, 2024, doi: 10.1007/s10522-024-10094-x.
75. B. Lopes da Costa et al., “Clinical and Therapeutic Evaluation of the Ten Most Prevalent CRB1 Mutations,” Biomedicines, 2023, doi: 10.3390/biomedicines11020385.
76. K. S. Manning, A. N. Rao, M. Castro, and T. A. Cooper, “BNANC Gapmers Revert Splicing and Reduce RNA Foci with Low Toxicity in Myotonic Dystrophy Cells,” ACS Chem. Biol., 2017, doi: 10.1021/acschembio.7b00416.
77. S. Crilly et al., “Zebrafish drug screening identifies candidate therapies for neuroprotection after spontaneous intracerebral haemorrhage,” DMM Dis. Model. Mech., 2022, doi: 10.1242/dmm.049227.
78. J. L. Pérez-Salas, M. R. Moreno-Jiménez, N. E. Rocha-Guzmán, R. F. González-Laredo, L. Medina-Torres, and J. A. Gallegos-Infante, “In Vitro and Ex Vivo Models for Screening Topical Anti-Inflammatory Drugs,” 2023. doi: 10.3390/scipharm91020020.
79. S. Grissenberger et al., “High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma,” Cancer Lett., 2023, doi: 10.1016/j.canlet.2022.216028.
80. A. Setiya, V. Jani, U. Sonavane, and R. Joshi, “MolToxPred: small molecule toxicity prediction using machine learning approach,” RSC Adv., 2024, doi: 10.1039/d3ra07322j.
81. T. M. Anoop, R. Joseph P, M. PN, P. KP, G. Gopan, and S. Chacko, “Cutaneous Toxicities in Breast Cancer Patients Receiving Chemotherapy and Targeted Agents—An Observational Clinical Study,” Clin. Breast Cancer, 2021, doi: 10.1016/j.clbc.2021.01.009.
82. K. S. Rao and B. A. Schwetz, “Reproductive toxicity of environmental agents.,” 1982. doi: 10.1146/annurev.pu.03.050182.000245.
83. A. C. Barber et al., “Repair of the degenerate retina by photoreceptor transplantation,” Proc. Natl. Acad. Sci. U. S. A., 2013, doi: 10.1073/pnas.1212677110.
84. S. Sugita et al., “HLA-matched allogeneic IPS cells-derived rpe transplantation for macular degeneration,” J. Clin. Med., 2020, doi: 10.3390/jcm9072217.
85. F. Ghosh, B. Juliusson, K. Arnér, and B. Ehinger, “Partial and full-thickness neuroretinal transplants,” Exp. Eye Res., 1999, doi: 10.1006/exer.1998.0582.
86. D. Patrício, J. Santiago, J. F. Mano, and M. Fardilha, “Organoids of the male reproductive system: Challenges, opportunities, and their potential use in fertility research,” 2023. doi: 10.1002/wsbm.1590.
87. C. K. Baker and J. G. Flannery, “Innovative Optogenetic Strategies for Vision Restoration,” Front. Cell. Neurosci., 2018, doi: 10.3389/fncel.2018.00316.
88. J. Mingaila, A. Atzeni, and A. Burokas, “A Comparison of Methods of Gut Microbiota Transplantation for Preclinical Studies,” Int. J. Mol. Sci., 2023, doi: 10.3390/ijms241512005.
89. N. Cross, C. van Steen, Y. Zegaoui, A. Satherley, and L. Angelillo, “Current and Future Treatment of Retinitis Pigmentosa,” Clin. Ophthalmol., 2022, doi: 10.2147/OPTH.S370032.
90. N. Vasli et al., “Next generation sequencing for molecular diagnosis of neuromuscular diseases,” Acta Neuropathol., 2012, doi: 10.1007/s00401-012-0982-8.
91. C. M. Sande et al., “Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms,” J. Mol. Diagnostics, 2023, doi: 10.1016/j.jmoldx.2022.11.005.
92. G. Hamm et al., “Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessment,” Arch. Toxicol., 2022, doi: 10.1007/s00204-021-03197-8.
93. M. Paques et al., “High-resolution imaging of retinal cells in the living eye,” Eye, 2007, doi: 10.1038/sj.eye.6702882.

94. M. Völker et al., “In vivo assessment of subretinally implanted microphotodiode arrays in cats by optical coherence tomography and fluorescein angiography,” Graefe’s Arch. Clin. Exp. Ophthalmol., 2004, doi: 10.1007/s00417-004-0935-6.
95. M. E. McClements et al., “Tropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids,” Transl. Vis. Sci. Technol., 2022, doi: 10.1167/tvst.11.4.3.
96. E. Aboualizadeh et al., “Imaging Transplanted Photoreceptors in Living Nonhuman Primates with Single-Cell Resolution,” Stem Cell Reports, 2020, doi: 10.1016/j.stemcr.2020.06.019.
97. A. J. Schreiner et al., “Comparison of meniscal allograft transplantation techniques using a preclinical canine model,” J. Orthop. Res., 2021, doi: 10.1002/jor.24668.
98. P. Gu, L. J. Harwood, X. Zhang, M. Wylie, W. J. Curry, and T. Cogliati, “Isolation of retinal progenitor and stem cells from the porcine eye,” Mol. Vis., 2007.
99. R. Sharma et al., “Clinical-grade stem cell-derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs,” Sci. Transl. Med., 2019, doi: 10.1126/scitranslmed.aat5580.
100. D. M. Waldner, F. Visser, A. J. Fischer, N. T. Bech-Hansen, and W. K. Stell, “Avian Adeno-associated viral transduction of the postembryonic chicken retina,” Transl. Vis. Sci. Technol., 2019, doi: 10.1167/tvst.8.4.1.
101. V. Mansouri, “X-Linked Retinitis Pigmentosa Gene Therapy: Preclinical Aspects,” 2023. doi: 10.1007/s40123-022-00602-y.
102. [102] S. Watanabe, R. Sanuki, S. Ueno, T. Koyasu, T. Hasegawa, and T. Furukawa, “Tropisms of AAV for Subretinal Delivery to the Neonatal Mouse Retina and Its Application for In Vivo Rescue of Developmental Photoreceptor Disorders,” PLoS One, 2013, doi: 10.1371/journal.pone.0054146.
103. “122. A Long-Term Study of AAV Vector-Mediated Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) Due to RP2 Mutation,” Mol. Ther., 2014, doi: 10.1016/s1525-0016(16)35135-8.
104. M. E. McClements, A. R. Barnard, P. C. Issa, and R. E. Maclaren, “Assessment of AAV dual vector safety in the ABCA4−/− mouse model of stargardt disease,” Transl. Vis. Sci. Technol., 2020, doi: 10.1167/tvst.9.7.20.
105. K. Xue and R. E. MacLaren, “Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases,” 2020. doi: 10.1080/13543784.2020.1804853.
106. [106] S. M. Caruso et al., “Prime Editing Strategy to Install the PRPH2 c.828+1G>A Mutation,” in Advances in Experimental Medicine and Biology, 2023. doi: 10.1007/978-3-031-27681-1_15.
107. E. Zaks-Makhina, Y. Kim, E. Aizenman, and E. S. Levitan, “Novel Neuroprotective K+ Channel Inhibitor Identified by High-Throughput Screening in Yeast,” Mol. Pharmacol., 2004, doi: 10.1124/mol.65.1.214.
108. K. B. un. Choo et al., “Oxidative stress-induced premature senescence in Wharton’s jelly-derived mesenchymal stem cells,” Int. J. Med. Sci., 2014, doi: 10.7150/ijms.8356.
109. C. Scheeder, F. Heigwer, and M. Boutros, “Machine learning and image-based profiling in drug discovery,” 2018. doi: 10.1016/j.coisb.2018.05.004.
110. D. Testart-Paillet, P. Girard, B. You, G. Freyer, C. Pobel, and B. Tranchand, “Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice,” 2007. doi: 10.1016/j.critrevonc.2007.01.005.
111. T. Denayer, T. Stöhrn, and M. Van Roy, “Animal models in translational medicine: Validation and prediction,” New Horizons Transl. Med., 2014, doi: 10.1016/j.nhtm.2014.08.001.
112. A. S. Tenforde et al., “Telehealth in PM&R: Past, present, and future in clinical practice and opportunities for translational research,” PM R, 2023, doi: 10.1002/pmrj.13029.
113. A. Markowska, D. Koziorowski, and S. Szlufik, “Microglia and Stem Cells for Ischemic Stroke Treatment—Mechanisms, Current Status, and Therapeutic Challenges,” 2023. doi: 10.31083/j.fbl2810269.
114. G. Choi, T. J. Moehling, and R. J. Meagher, “Advances in RT-LAMP for COVID-19 testing and diagnosis,” 2023. doi: 10.1080/14737159.2023.2169071.
115. J. M. Bailey, A. N. Oliveri, and E. D. Levin, “Pharmacological analyses of learning and memory in zebrafish (Danio rerio),” 2015. doi: 10.1016/j.pbb.2015.03.006.
116. . Qu et al., “The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer,” 2021. doi: 10.1177/1758835921992968.
117. I. Martinelli, S. K. Tayebati, D. Tomassoni, G. Nittari, P. Roy, and F. Amenta, “Brain and Retinal Organoids for Disease Modeling: The Importance of In Vitro Blood–Brain and Retinal Barriers Studies,” 2022. doi: 10.3390/cells11071120.

118. K. C. Eldred and T. A. Reh, “Human retinal model systems: Strengths, weaknesses, and future directions,” Dev. Biol., 2021, doi: 10.1016/j.ydbio.2021.09.001.
119. W. Shen et al., “Retinogenesis in a Dish: Bibliometric Analysis and Visualization of Retinal Organoids From 2011 to 2022,” Cell Transplant., 2023, doi: 10.1177/09636897231214321.
120. J. R. Soucy et al., “Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium,” 2023. doi: 10.1186/s13024-023-00655-y.
121. J. Oswald, C. Pernstich, and P. Baranov, “Allotransplantation of Functional Retinal Ganglion Cells for Glaucoma,” Mol. Ther., 2020.
122. Y. P. Novikova, V. A. Poplinskaya, and E. N. Grigoryan, “Organotypic Culturing as a Way to Study Recovery Opportunities of the Eye Retina in Vertebrates and Humans,” Russ. J. Dev. Biol., 2020, doi: 10.1134/s1062360420010063.
123. F. Colombo et al., “Two-Photon Laser Printing to Mechanically Stimulate Multicellular Systems in 3D,” Adv. Funct. Mater., 2024, doi: 10.1002/adfm.202303601.